Zepimax Tirzepatide: Understanding the Dosing Evidence Behind Tirzepatide in the UK

Why SURMOUNT-1 matters when you're reading about tirzepatide dosing

The SURMOUNT-1 trial is the clearest window into how tirzepatide performs across its dose range. Across the 72-week study, average weight loss climbed with each successive dose: participants on 5 mg lost roughly 15%, those on 10 mg around 19%, and those on 15 mg approximately 20–21%. These were not cherry-picked results from the best performers — they were intention-to-treat analyses across a large, randomised cohort. NICE cited this data when it recommended tirzepatide in its technology appraisal TA1026, published in December 2024 and updated the following September, for adults with a BMI of 35 or above and at least one weight-related health condition.

What the trial also showed is that the early doses are not wasted weeks. Starting at 2.5 mg and stepping up deliberately gives the body time to adapt to slower gastric emptying and the appetite-suppressing effects of the medicine. Gastrointestinal side effects (nausea, indigestion, loose stools) are most common in the adjustment period and typically settle as the body accommodates each new level. The titration schedule exists because the evidence was built around it; it is not an optional ladder to skip. For a broader look at how the dose range is structured, the tirzepatide dosing overview covers this in detail.

What happens at each step (and where the prescriber's judgement comes in

A question our prescribers hear most weeks runs something like: 'Can I just stay on the lower dose if it's working?' The honest answer is yes) clinical guidance does not require titration to the maximum dose if you are losing weight at a pace your prescriber considers appropriate and your tolerance is good. Titration is a tool, not a contract.

That said, the licensed UK strengths run from 2.5 mg through 5, 7.5, 10, 12.5, and 15 mg, each pen supplying four weekly doses. The 5 mg dose is the first therapeutic step after the starter pen, and many people notice meaningful appetite change there. The maximum licensed dose of 15 mg is the ceiling, not the target: NICE's recommendation includes a review clause, if less than 5% weight loss is achieved after six months at the highest tolerated dose, continuing should be assessed. Your prescriber tracks this. At nume (sorry) at nume, every repeat order is clinically re-reviewed before dispatch, so dose decisions are never left on autopilot.

Zepimax, informal names, and the importance of knowing what you're actually taking

Terms like 'Zepimax' circulate in online forums and across some international sites, sometimes attached to products described as tirzepatide. The MHRA's licensed product in the UK is Mounjaro only, the branded KwikPen manufactured by Eli Lilly and supplied through the authorised UK supply chain. Purchasing a product labelled with an unfamiliar name, or ordering tirzepatide from a seller who does not require a prescription and a proper clinical assessment, carries real risks.

The MHRA has warned publicly about counterfeit weight-loss pens sold online, including fake pens that have contained entirely different substances. Any pharmacy dispensing tirzepatide legally in the UK must be registered with the GPhC, you can check any online pharmacy's registration directly at the GPhC pharmacy register. Unusual brand names, prices well below the market, and sellers who skip clinical assessment are all red flags worth taking seriously. If you want context on what legitimate private treatment typically costs, the Mounjaro pricing page sets that out clearly.

What eligibility for tirzepatide actually looks like under UK guidance

The SmPC licences tirzepatide for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, prediabetes, type 2 diabetes, or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK guidance, typically 2.5 kg/m² less than the standard figures. BMI alone does not decide suitability; a prescriber reviews medical history, current medicines, and any contraindications before approving treatment.

Tirzepatide is not recommended during pregnancy, breastfeeding, or when trying to conceive, and it is not licensed for under-18s. Certain conditions (including a history of medullary thyroid carcinoma or MEN2) require particular clinical scrutiny. The NHS medicines page for tirzepatide covers contraindications in patient-friendly terms and is worth reading before any consultation. If you're weighing whether this treatment is right for your situation, the weight-loss treatment overview is a good starting point before speaking to a prescriber.

If you'd like a prescriber to review your circumstances, starting a free consultation with our clinical team is the natural next step.